Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18206 participants.
Also called NCT01107886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 18,206 participants
- Sponsor
- Registry
-
NCT01107886
-
- Other papers using this trial's data
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
- Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
- Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong SAR China, Hungary, India, Israel, Italy, Mexico, Netherlands, Peru, Poland, Puerto Rico, Russia, South Africa, Spain, Sweden, Taiwan, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01107886. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
- Acronym
- SAVOR- TIMI 53
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01107886- Content hash
c40846c4fd70940b6d670371539ed23d99794cdc68beda62f1a168f52dd40ad9